Alexander's Inc. logo

Alexander's Inc. (ALX)

Market Closed
8 Dec, 20:00
NYSE NYSE
$
213. 47
+1.65
+0.78%
$
1.08B Market Cap
- P/E Ratio
18% Div Yield
25,734 Volume
- Eps
$ 211.82
Previous Close
Day Range
210.06 213.68
Year Range
184.76 260.84
Want to track ALX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 62 days
Best Income Stocks to Buy for March 25th

Best Income Stocks to Buy for March 25th

ALX, HAFC and HBNC made it to the Zacks Rank #1 (Strong Buy) income stocks list on March 25, 2025.

Zacks | 8 months ago
Is Alexander's (ALX) Outperforming Other Finance Stocks This Year?

Is Alexander's (ALX) Outperforming Other Finance Stocks This Year?

Here is how Alexander's (ALX) and Banco Bilbao (BBVA) have performed compared to their sector so far this year.

Zacks | 8 months ago
Best Income Stocks to Buy for March 13th

Best Income Stocks to Buy for March 13th

ALX, HAFC and FHB made it to the Zacks Rank #1 (Strong Buy) income stocks list on March 13, 2025.

Zacks | 9 months ago
Best Income Stocks to Buy for March 11th

Best Income Stocks to Buy for March 11th

ALX, VLY and HAFC made it to the Zacks Rank #1 (Strong Buy) income stocks list on March 11, 2025.

Zacks | 9 months ago
Alexander's (ALX) Q4 FFO and Revenues Surpass Estimates

Alexander's (ALX) Q4 FFO and Revenues Surpass Estimates

Alexander's (ALX) came out with quarterly funds from operations (FFO) of $4.06 per share, beating the Zacks Consensus Estimate of $3.71 per share. This compares to FFO of $4.99 per share a year ago.

Zacks | 10 months ago
Alexander's: Bloomberg Lease Secured, Is The Dividend Safe

Alexander's: Bloomberg Lease Secured, Is The Dividend Safe

Alexander's has dipped materially from its 52-week high following a spike in the US 10-year Treasury yield. The REIT generated fiscal 2024 third-quarter FFO of $2.84 per share, down from its year-ago comp. A $354.8 million cash and cash equivalents position helps to provide a buffer for the REIT, but 2025 debt maturities are heavy and will pose a challenge.

Seekingalpha | 10 months ago
Alexander's Is A Good Business That The Market Has Overestimated

Alexander's Is A Good Business That The Market Has Overestimated

Alexander's, Inc. has underperformed since 2019, with a -1.7% TSR compared to SPY's 113%, due to declining profitability and rich valuations. Despite increasing NOPAT since 2020, the Company's GAAP net income and NOPAT margins have declined from 2019 highs, impacting overall profitability. Management has created value with $154 million in economic earnings since 2019, but ALX remains overvalued with unrealistic growth expectations.

Seekingalpha | 1 year ago
Alexander's (ALX) Tops Q3 FFO and Revenue Estimates

Alexander's (ALX) Tops Q3 FFO and Revenue Estimates

Alexander's (ALX) came out with quarterly funds from operations (FFO) of $2.84 per share, beating the Zacks Consensus Estimate of $2.57 per share. This compares to FFO of $3.63 per share a year ago.

Zacks | 1 year ago
Best Income Stocks to Buy for September 18th

Best Income Stocks to Buy for September 18th

ALX, JSAIY and NBTB made it to the Zacks Rank #1 (Strong Buy) income stocks list on September 18, 2024.

Zacks | 1 year ago
New Strong Buy Stocks for September 18th

New Strong Buy Stocks for September 18th

SN, ALX, BPOP, ARCAY and JSAIY have been added to the Zacks Rank #1 (Strong Buy) List on September 18, 2024.

Zacks | 1 year ago
Best Income Stocks to Buy for September 13th

Best Income Stocks to Buy for September 13th

BANF, ALX and BPRN made it to the Zacks Rank #1 (Strong Buy) income stocks list on September 13, 2024.

Zacks | 1 year ago
ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations

ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations

ALX Oncology's Evorpacept, a first-in-class CD47 inhibitor, shows promising results in cancer treatment with reduced side effects and a favorable safety profile. Evorpacept's combination with TRP demonstrated improved response rates and longer duration of response in HER2-positive gastric and GEJ cancer trials. The ASPEN-06 trial also showed favorable results, with a 40.3% ORR in HER2-positive gastric/GEJ cancer, higher than the control group's 26.6%.

Seekingalpha | 1 year ago
Loading...
Load More